Analysis depression
Analysis depression is defined as a distinct decrease in a person's overall ability to process information[1][2][3] and logically or creatively analyze concepts, ideas, and scenarios.[4] The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.
Analysis suppression is often accompanied by other coinciding effects such as sedation, thought deceleration, and emotion suppression. It is most commonly induced under the influence of heavy dosages of antipsychotic compounds,[1][2][4] and is associated with long term use of such drugs[5] like quetiapine, haloperidol, and risperidone. However, it can also occur in a less consistent form under the influence of heavy dosages of dissociatives, cannabinoids,[3] and GABAergic depressants[6].
Psychoactive substances
Compounds within our psychoactive substance index which may cause this effect include:
- 1,4-Butanediol
- 2-Fluorodeschloroketamine
- 2M2B
- 3-MeO-PCE
- 3-MeO-PCMo
- 4-MeO-PCP
- 5F-AKB48
- 5F-PB-22
- AB-FUBINACA
- APICA
- Alcohol
- Alprazolam
- Amanita muscaria
- Baclofen
- Barbiturates
- Benzodiazepines
- Bromazolam
- Cannabis
- Carisoprodol
- Clonazepam
- Clonazolam
- DOB
- Deschloroetizolam
- Deschloroketamine
- Dextromethorphan
- Diazepam
- Diclazepam
- Diphenhydramine
- Diphenidine
- Ephenidine
- Eszopiclone
- Etizolam
- F-Phenibut
- Flualprazolam
- Flubromazepam
- Flubromazolam
- Flunitrazepam
- Flunitrazolam
- GBL
- GHB
- Gabapentin
- Gaboxadol
- HXE
- JWH-018
- JWH-073
- Ketamine
- Lorazepam
- Memantine
- Methaqualone
- Methoxetamine
Experience reports
Annectdotal reports which describe this effect with our experience index include:
- Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)
- Experience: 25mg 2C-E (oral) - A mindblowing experience
- Experience:1 hit LSD (unknown dosage) - Choose Asia
- Experience:25mg 2C-B - Hard raving at home
- Experience:2mg Etizolam - Here be dragons
- Experience:3mg Etizolam - A Comedown Drug
- Experience:50mg - Diphenidine ride
- Experience:DXM and Cannabis: 100mg - Unexpected Strong Trip
- Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death
- Experience:Unknown dose - Supermarket dislocation and biking
- Experience:~150mg MDA(oral) - a case of mistaken identity
See also
External links
References
- ↑ 1.0 1.1 Knowles, Emma E.M.; David, Anthony S.; Reichenberg, Abraham (2010). "Processing Speed Deficits in Schizophrenia: Reexamining the Evidence". American Journal of Psychiatry. 167 (7): 828–835. doi:10.1176/appi.ajp.2010.09070937. ISSN 0002-953X.
- ↑ 2.0 2.1 Takeuchi, H.; Suzuki, T.; Remington, G.; Bies, R. R.; Abe, T.; Graff-Guerrero, A.; Watanabe, K.; Mimura, M.; Uchida, H. (2013). "Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study". Schizophrenia Bulletin. 39 (5): 993–998. doi:10.1093/schbul/sbt090. ISSN 0586-7614.
- ↑ 3.0 3.1 Fried, P; Watkinson, B; Gray, R (2005). "Neurocognitive consequences of marihuana—a comparison with pre-drug performance". Neurotoxicology and Teratology. 27 (2): 231–239. doi:10.1016/j.ntt.2004.11.003. ISSN 0892-0362.
- ↑ 4.0 4.1 Kawai, Nobutoshi; Yamakawa, Yuriko; Baba, Atsuomi; Nemoto, Kiyotaka; Tachikawa, Hirokazu; Hori, Takafumi; Asada, Takashi; Iidaka, Tetsuya (2006). "High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 (6): 1009–1014. doi:10.1016/j.pnpbp.2006.03.013. ISSN 0278-5846.
- ↑ Husa, Anja P.; Moilanen, Jani; Murray, Graham K.; Marttila, Riikka; Haapea, Marianne; Rannikko, Irina; Barnett, Jennifer H.; Jones, Peter B.; Isohanni, Matti; Remes, Anne M.; Koponen, Hannu; Miettunen, Jouko; Jääskeläinen, Erika (2017). "Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort". Psychiatry Research. 247: 130–138. doi:10.1016/j.psychres.2016.10.085. ISSN 0165-1781.
- ↑ Paraherakis, Antonios; Charney, Dara A.; Gill, Kathryn (2009). "NEUROPSYCHOLOGICAL FUNCTIONING IN SUBSTANCE-DEPENDENT PATIENTS". Substance Use & Misuse. 36 (3): 257–271. doi:10.1081/JA-100102625. ISSN 1082-6084.